EL
Elicio Therapeutics, Inc.
ELTX · NASDAQ
$1.81 -2.16% (-$0.04)
1M -15.14%
Market Cap $34.5M
P/E Ratio -
Div. Yield -
ROE 1,266.43%
Bulios Fair Price
$1.6
11.6% downside
Current Price
$1.81
Undervalued Fair Value Overvalued
According to Bulios Fair Price, ELTX is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Weak
2/9Valuation
46 /100
Fair P/B 4.35x
P/E N/A
EV/EBITDA N/A
Growth
0 /100
Declining Book val. growth 43.17%
EPS growth N/A
Rev. growth N/A
Profitability
-
N/A Gross margin N/A
Net margin N/A
FCF margin N/A
Quality
0 /100
Poor ROIC 163.43%
ROE 1,266.43%
Asset turnover 0.00x
Debt
35 /100
Moderate Debt/Equity 1.78x
Current ratio 2.77x
Int. coverage -26.18x
Stability
45 /100
Moderate Beta 1.86x
EPS volatility 9.01%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about ELTX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Robert T. Connelly
Employees
33
Headquarters
Boston
Upcoming events
12 NOV
Earnings
Upcoming earnings report